Ezetimibe plus statin combination versus double-dose statin in patients with dyslipidemia and atherosclerotic cardiovascular disease risk: a comprehensive systematic review and meta-analysis of 47 randomized controlled trials.
Level 1 - systematic review of randomized trials
Systematic review and meta-analysis of 47 randomized controlled trials
PubMed 40557229 · doi:10.1080/08998280.2025.2487966
What was done
A systematic review and meta-analysis of randomized controlled trials identified from PubMed, Embase, Cochrane, Scopus, and Web of Science up to December 2023. The authors compared the efficacy and safety of ezetimibe plus statin therapy versus doubling the dose of the same statin in patients with dyslipidemia and atherosclerotic cardiovascular disease risk. Outcomes were pooled using a random-effects model.
What was found
Across 47 randomized controlled trials with 18,592 patients, ezetimibe plus statin therapy significantly reduced LDL cholesterol (P < 0.001), triglycerides (P = 0.019), and total cholesterol (P < 0.001), and significantly increased target LDL achievement (P < 0.0001) compared to double-dose statin therapy. No significant differences were observed for HDL cholesterol, any adverse events, all-cause mortality, myocardial infarction, angina, or nonfatal stroke. Severe adverse events were significantly higher in the combination group (P = 0.03). Specific effect sizes (point estimates, mean differences, risk ratios, and confidence intervals) were not reported in the abstract.
Why it matters
Adding ezetimibe is more effective for lowering LDL and achieving lipid targets than doubling the statin dose. However, this lipid improvement was not accompanied by detectable reductions in major adverse cardiovascular events or mortality in the aggregated trial data.
Limits
The abstract omits numeric effect sizes and confidence intervals, providing only p-values. Most included trials were likely powered for surrogate lipid biomarkers rather than long-term clinical cardiovascular endpoints, limiting conclusions on hard outcomes. The clinical significance of the higher rate of severe adverse events remains uncertain given their rarity and lack of clear medication attribution.
Cited by
- supports Combining a statin with Zetia (ezetimibe) has been shown to be very effective at lowering cholesterol.